{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T01:42:28Z","timestamp":1794447748922,"version":"4.9.1"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS127188"],"award-info":[{"award-number":["R01NS127188"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS120926"],"award-info":[{"award-number":["R01NS120926"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["P30ES017885"],"award-info":[{"award-number":["P30ES017885"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["R01ES030049"],"award-info":[{"award-number":["R01ES030049"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000971","name":"Amyotrophic Lateral Sclerosis Association","doi-asserted-by":"publisher","award":["20-IIA-532"],"award-info":[{"award-number":["20-IIA-532"]}],"id":[{"id":"10.13039\/100000971","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-64622-5","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:11:06Z","timestamp":1761916266000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Gene expression signatures from whole blood predict amyotrophic lateral sclerosis case status and survival"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6029-7123","authenticated-orcid":false,"given":"Yue","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5575-2494","authenticated-orcid":false,"given":"Masha G.","family":"Savelieff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiayan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4651-781X","authenticated-orcid":false,"given":"Kai","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-6535","authenticated-orcid":false,"given":"Minghua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5843-0925","authenticated-orcid":false,"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayatri","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5064-9022","authenticated-orcid":false,"given":"Stacey A.","family":"Sakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6366-8206","authenticated-orcid":false,"given":"Lili","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9072-8184","authenticated-orcid":false,"given":"Samuel J.","family":"Teener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9605-6337","authenticated-orcid":false,"given":"Kelly M.","family":"Bakulski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0527-2446","authenticated-orcid":false,"given":"Bryan J.","family":"Traynor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alla","family":"Karnovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart A.","family":"Batterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0736-2149","authenticated-orcid":false,"given":"Junguk","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-6637","authenticated-orcid":false,"given":"Stephen A.","family":"Goutman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6155-5702","authenticated-orcid":false,"given":"Maureen A.","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9162-2694","authenticated-orcid":false,"given":"Eva L.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"64622_CR1","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1111\/ene.15874","volume":"30","author":"KG Gwathmey","year":"2023","unstructured":"Gwathmey, K. G. et al. Diagnostic delay in amyotrophic lateral sclerosis. Eur. J. Neurol. 30, 2595\u20132601 (2023).","journal-title":"Eur. J. Neurol."},{"key":"64622_CR2","first-page":"504","volume":"36","author":"JF Vazquez-Costa","year":"2021","unstructured":"Vazquez-Costa, J. F. et al. Analysis of the diagnostic pathway and delay in patients with amyotrophic lateral sclerosis in the Valencian Community. Neurologia (Engl. Ed.) 36, 504\u2013513 (2021).","journal-title":"Neurologia (Engl. Ed.)"},{"key":"64622_CR3","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0140-6736(22)01272-7","volume":"400","author":"EL Feldman","year":"2022","unstructured":"Feldman, E. L. et al. Amyotrophic lateral sclerosis. Lancet 400, 1363\u20131380 (2022).","journal-title":"Lancet"},{"key":"64622_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117054","volume":"417","author":"D Richards","year":"2020","unstructured":"Richards, D., Morren, J. A. & Pioro, E. P. Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis. J. Neurol. Sci. 417, 117054 (2020).","journal-title":"J. Neurol. Sci."},{"key":"64622_CR5","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1136\/jnnp.2010.235952","volume":"82","author":"A Chi\u00f2","year":"2011","unstructured":"Chi\u00f2, A., Calvo, A., Moglia, C., Mazzini, L. & Mora, G. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J. Neurol. Neurosurg. Psychiatry 82, 740\u2013746 (2011).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"64622_CR6","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/mus.27724","volume":"66","author":"NJ Thakore","year":"2022","unstructured":"Thakore, N. J., Lapin, B. R., Mitsumoto, H. & Pooled Resource Open-Access Als Clinical Trials, C. Early initiation of riluzole may improve absolute survival in amyotrophic lateral sclerosis. Muscle Nerve 66, 702\u2013708 (2022).","journal-title":"Muscle Nerve"},{"key":"64622_CR7","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1212\/WNL.0b013e3181bc01a4","volume":"73","author":"RG Miller","year":"2009","unstructured":"Miller, R. G. et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive\/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73, 1227\u20131233 (2009).","journal-title":"Neurology"},{"key":"64622_CR8","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/ana.25276","volume":"84","author":"M Benatar","year":"2018","unstructured":"Benatar, M., Wuu, J., Andersen, P. M., Lombardi, V. & Malaspina, A. Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann. Neurol. 84, 130\u2013139 (2018).","journal-title":"Ann. Neurol."},{"key":"64622_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-61655-6","volume":"14","author":"G Giacomucci","year":"2024","unstructured":"Giacomucci, G. et al. Future perspective and clinical applicability of the combined use of plasma phosphorylated tau 181 and neurofilament light chain in Subjective Cognitive Decline and Mild Cognitive Impairment. Sci. Rep. 14, 11307 (2024).","journal-title":"Sci. Rep."},{"key":"64622_CR10","doi-asserted-by":"publisher","first-page":"102290","DOI":"10.1016\/j.arr.2024.102290","volume":"96","author":"S Lista","year":"2024","unstructured":"Lista, S. et al. A critical appraisal of blood-based biomarkers for Alzheimer\u2019s disease. Ageing Res Rev. 96, 102290 (2024).","journal-title":"Ageing Res Rev."},{"key":"64622_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcae130","volume":"6","author":"A Zarkali","year":"2024","unstructured":"Zarkali, A. et al. Neuroimaging and plasma evidence of early white matter loss in Parkinson\u2019s disease with poor outcomes. Brain Commun. 6, fcae130 (2024).","journal-title":"Brain Commun."},{"key":"64622_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102807","volume":"56","author":"S Bittner","year":"2020","unstructured":"Bittner, S. et al. Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. EBioMedicine 56, 102807 (2020).","journal-title":"EBioMedicine"},{"key":"64622_CR13","doi-asserted-by":"publisher","first-page":"986","DOI":"10.2337\/dc23-2208","volume":"47","author":"LL M\u00e4\u00e4tt\u00e4","year":"2024","unstructured":"M\u00e4\u00e4tt\u00e4, L. L. et al. Longitudinal Change in Serum Neurofilament Light Chain in Type 2 Diabetes and Early Diabetic Polyneuropathy: ADDITION-Denmark. Diabetes Care 47, 986\u2013994 (2024).","journal-title":"Diabetes Care"},{"key":"64622_CR14","doi-asserted-by":"publisher","first-page":"fcae132","DOI":"10.1093\/braincomms\/fcae132","volume":"6","author":"CA Leckey","year":"2024","unstructured":"Leckey, C. A. et al. CSF neurofilament light chain profiling and quantitation in neurological diseases. Brain Commun. 6, fcae132 (2024).","journal-title":"Brain Commun."},{"key":"64622_CR15","doi-asserted-by":"publisher","unstructured":"Beydoun, M. A. et al. Serum neurofilament light chain as a prognostic marker of all-cause mortality in a national sample of US adults. Eur. J. Epidemiol. https:\/\/doi.org\/10.1007\/s10654-024-01131-7 (2024).","DOI":"10.1007\/s10654-024-01131-7"},{"key":"64622_CR16","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1200\/JCO.22.02511","volume":"41","author":"JS Parker","year":"2023","unstructured":"Parker, J. S. et al. Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. J. Clin. Oncol. 41, 4192\u20134199 (2023).","journal-title":"J. Clin. Oncol."},{"key":"64622_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-177","volume":"14","author":"T Nielsen","year":"2014","unstructured":"Nielsen, T. et al. Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer 14, 177 (2014).","journal-title":"BMC Cancer"},{"key":"64622_CR18","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1001\/jamaoncol.2024.0455","volume":"10","author":"JJ Tosoian","year":"2024","unstructured":"Tosoian, J. J. et al. Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer. JAMA Oncol. 10, 726\u2013736 (2024).","journal-title":"JAMA Oncol."},{"key":"64622_CR19","doi-asserted-by":"publisher","first-page":"e0198874","DOI":"10.1371\/journal.pone.0198874","volume":"13","author":"W van Rheenen","year":"2018","unstructured":"van Rheenen, W. et al. Whole blood transcriptome analysis in amyotrophic lateral sclerosis: A biomarker study. PLoS One 13, e0198874 (2018).","journal-title":"PLoS One"},{"key":"64622_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-1909-0","volume":"17","author":"WR Swindell","year":"2019","unstructured":"Swindell, W. R., Kruse, C. P. S., List, E. O., Berryman, D. E. & Kopchick, J. J. ALS blood expression profiling identifies new biomarkers, patient subgroups, and evidence for neutrophilia and hypoxia. J. Transl. Med. 17, 170 (2019).","journal-title":"J. Transl. Med"},{"key":"64622_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12943","volume":"49","author":"N Grima","year":"2023","unstructured":"Grima, N. et al. RNA sequencing of peripheral blood in amyotrophic lateral sclerosis reveals distinct molecular subtypes: Considerations for biomarker discovery. Neuropathol. Appl Neurobiol. 49, e12943 (2023).","journal-title":"Neuropathol. Appl Neurobiol."},{"key":"64622_CR22","doi-asserted-by":"publisher","unstructured":"Goutman, S. A. et al. Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurol, https:\/\/doi.org\/10.1016\/S1474-4422(21)00465-8 (2022).","DOI":"10.1016\/S1474-4422(21)00465-8"},{"key":"64622_CR23","doi-asserted-by":"publisher","unstructured":"Goutman, S. A. et al. Metabolomics identifies shared lipid pathways in independent amyotrophic lateral sclerosis cohorts. Brain, https:\/\/doi.org\/10.1093\/brain\/awac025 (2022).","DOI":"10.1093\/brain\/awac025"},{"key":"64622_CR24","doi-asserted-by":"crossref","unstructured":"Murdock, B. J., Goutman, S. A., Boss, J., Kim, S. & Feldman, E. L. Amyotrophic Lateral Sclerosis Survival Associates With Neutrophils in a Sex-specific Manner. Neurol. Neuroimmunol. Neuroinflamm. 8, e953 (2021).","DOI":"10.1212\/NXI.0000000000000953"},{"key":"64622_CR25","doi-asserted-by":"publisher","unstructured":"Murdock, B. J. et al. Natural killer cells associate with amyotrophic lateral sclersois in a sex- and age-dependent manner. JCI Insight, https:\/\/doi.org\/10.1172\/jci.insight.147129 (2021).","DOI":"10.1172\/jci.insight.147129"},{"key":"64622_CR26","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200241","volume":"11","author":"BJ Murdock","year":"2024","unstructured":"Murdock, B. J. et al. Peripheral Immune Profiles Predict ALS Progression in an Age- and Sex-Dependent Manner. Neurol. Neuroimmunol. Neuroinflamm 11, e200241 (2024).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"key":"64622_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20191-3","volume":"11","author":"D Jutzi","year":"2020","unstructured":"Jutzi, D. et al. Aberrant interaction of FUS with the U1 snRNA provides a molecular mechanism of FUS induced amyotrophic lateral sclerosis. Nat. Commun. 11, 6341 (2020).","journal-title":"Nat. Commun."},{"key":"64622_CR28","doi-asserted-by":"publisher","first-page":"26314","DOI":"10.1074\/jbc.M401800200","volume":"279","author":"H Mao","year":"2004","unstructured":"Mao, H. et al. RGS17\/RGSZ2, a novel regulator of Gi\/o, Gz, and Gq signaling. J. Biol. Chem. 279, 26314\u201326322 (2004).","journal-title":"J. Biol. Chem."},{"key":"64622_CR29","doi-asserted-by":"crossref","unstructured":"Chen T., Guestrin C. XGBoost: A Scalable Tree Boosting System. In: Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining). Association for Computing Machinery (2016).","DOI":"10.1145\/2939672.2939785"},{"key":"64622_CR30","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1001\/jamaneurol.2017.2255","volume":"74","author":"BJ Murdock","year":"2017","unstructured":"Murdock, B. J. et al. Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression. JAMA Neurol. 74, 1446\u20131454 (2017).","journal-title":"JAMA Neurol."},{"key":"64622_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.773288","volume":"13","author":"C Figueroa-Romero","year":"2022","unstructured":"Figueroa-Romero, C. et al. Tofacitinib suppresses natural killer cells in vitro and in vivo: implications for amyotrophic lateral sclerosis. Front Immunol. 13, 773288 (2022).","journal-title":"Front Immunol."},{"key":"64622_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105383","volume":"109","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y. et al. Epigenetic age acceleration is associated with occupational exposures, sex, and survival in amyotrophic lateral sclerosis. EBioMedicine 109, 105383 (2024).","journal-title":"EBioMedicine"},{"key":"64622_CR33","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.expneurol.2018.07.008","volume":"311","author":"MC Braun","year":"2019","unstructured":"Braun, M. C. et al. Defective daily temperature regulation in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 311, 305\u2013312 (2019).","journal-title":"Exp. Neurol."},{"key":"64622_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41586-022-04436-3","volume":"603","author":"AL Brown","year":"2022","unstructured":"Brown, A. L. et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature 603, 131\u2013137 (2022).","journal-title":"Nature"},{"key":"64622_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37630-6","volume":"14","author":"OJ Ziff","year":"2023","unstructured":"Ziff, O. J. et al. Integrated transcriptome landscape of ALS identifies genome instability linked to TDP-43 pathology. Nat. Commun. 14, 2176 (2023).","journal-title":"Nat. Commun."},{"key":"64622_CR36","doi-asserted-by":"publisher","first-page":"401","DOI":"10.7150\/jca.89665","volume":"15","author":"F Zhou","year":"2024","unstructured":"Zhou, F., Liu, Y., Liu, D., Xie, Y. & Zhou, X. Identification of basement membrane-related signatures for estimating prognosis, immune infiltration landscape and drug candidates in pancreatic adenocarcinoma. J. Cancer 15, 401\u2013417 (2024).","journal-title":"J. Cancer"},{"key":"64622_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-10-405","volume":"10","author":"CG Saris","year":"2009","unstructured":"Saris, C. G. et al. Weighted gene co-expression network analysis of the peripheral blood from Amyotrophic Lateral Sclerosis patients. BMC Genomics 10, 405 (2009).","journal-title":"BMC Genomics"},{"key":"64622_CR38","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S1474-4422(18)30089-9","volume":"17","author":"HJ Westeneng","year":"2018","unstructured":"Westeneng, H. J. et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 17, 423\u2013433 (2018).","journal-title":"Lancet Neurol."},{"key":"64622_CR39","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1212\/WNL.0000000000009559","volume":"95","author":"M Benatar","year":"2020","unstructured":"Benatar, M. et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology 95, e59\u2013e69 (2020).","journal-title":"Neurology"},{"key":"64622_CR40","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller, T. M. et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 387, 1099\u20131110 (2022).","journal-title":"N. Engl. J. Med"},{"key":"64622_CR41","doi-asserted-by":"publisher","first-page":"102844","DOI":"10.1016\/j.ebiom.2020.102844","volume":"59","author":"W Camu","year":"2020","unstructured":"Camu, W. et al. Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial. EBioMedicine 59, 102844 (2020).","journal-title":"EBioMedicine"},{"key":"64622_CR42","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1007\/s13311-022-01237-4","volume":"19","author":"M Benatar","year":"2022","unstructured":"Benatar, M. et al. Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 Variant Carriers: the ATLAS Study. Neurotherapeutics 19, 1248\u20131258 (2022).","journal-title":"Neurotherapeutics"},{"key":"64622_CR43","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.3390\/biomedinformatics4030093","volume":"4","author":"K Kadena","year":"2024","unstructured":"Kadena, K. & Ouzounoglou, E. Drug repurposing for amyotrophic lateral sclerosis based on gene expression similarity and structural similarity: a cheminformatics, genomic and network-based analysis. BioMedInformatics 4, 1713\u20131724 (2024).","journal-title":"BioMedInformatics"},{"key":"64622_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14774","volume":"8","author":"RL McLaughlin","year":"2017","unstructured":"McLaughlin, R. L. et al. Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. Nat. Commun. 8, 14774 (2017).","journal-title":"Nat. Commun."},{"key":"64622_CR45","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.mehy.2007.02.041","volume":"69","author":"EW Stommel","year":"2007","unstructured":"Stommel, E. W., Graber, D., Montanye, J., Cohen, J. A. & Harris, B. T. Does treating schizophrenia reduce the chances of developing amyotrophic lateral sclerosis?. Med Hypotheses 69, 1021\u20131028 (2007).","journal-title":"Med Hypotheses"},{"key":"64622_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1358568","volume":"15","author":"H Cortes-Flores","year":"2024","unstructured":"Cortes-Flores, H., Torrandell-Haro, G. & Brinton, R. D. Association between CNS-active drugs and risk of Alzheimer\u2019s and age-related neurodegenerative diseases. Front Psychiatry 15, 1358568 (2024).","journal-title":"Front Psychiatry"},{"key":"64622_CR47","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000448618","volume":"47","author":"F D\u2019Ovidio","year":"2016","unstructured":"D\u2019Ovidio, F. et al. Amyotrophic Lateral Sclerosis Incidence and Previous Prescriptions of Drugs for the Nervous System. Neuroepidemiology 47, 59\u201366 (2016).","journal-title":"Neuroepidemiology"},{"key":"64622_CR48","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.neuropharm.2013.07.027","volume":"75","author":"C Hempel","year":"2013","unstructured":"Hempel, C. et al. The phenothiazine-class antipsychotic drugs prochlorperazine and trifluoperazine are potent allosteric modulators of the human P2X7 receptor. Neuropharmacology 75, 365\u2013379 (2013).","journal-title":"Neuropharmacology"},{"key":"64622_CR49","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3389\/fnmol.2020.00093","volume":"13","author":"C Ruiz-Ruiz","year":"2020","unstructured":"Ruiz-Ruiz, C., Calzaferri, F. & Garc\u00eda, A. G. P2X7 Receptor Antagonism as a Potential Therapy in Amyotrophic Lateral Sclerosis. Front Mol. Neurosci. 13, 93 (2020).","journal-title":"Front Mol. Neurosci."},{"key":"64622_CR50","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s11481-023-10068-9","volume":"18","author":"C Zheng","year":"2023","unstructured":"Zheng, C. et al. Ibrutinib Delays ALS Installation and Increases Survival of SOD1(G93A) Mice by Modulating PI3K\/mTOR\/Akt Signaling. J. Neuroimmune Pharm. 18, 383\u2013396 (2023).","journal-title":"J. Neuroimmune Pharm."},{"key":"64622_CR51","doi-asserted-by":"crossref","unstructured":"Imamura, K. et al. The Src\/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci Transl Med. 9, eaaf3962 (2017).","DOI":"10.1126\/scitranslmed.aaf3962"},{"key":"64622_CR52","doi-asserted-by":"publisher","first-page":"101707","DOI":"10.1016\/j.eclinm.2022.101707","volume":"53","author":"K Imamura","year":"2022","unstructured":"Imamura, K. et al. Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial. EClinicalMedicine 53, 101707 (2022).","journal-title":"EClinicalMedicine"},{"key":"64622_CR53","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/bph.15221","volume":"178","author":"V Palomo","year":"2021","unstructured":"Palomo, V., Nozal, V., Rojas-Prats, E., Gil, C. & Martinez, A. Protein kinase inhibitors for amyotrophic lateral sclerosis therapy. Br. J. Pharm. 178, 1316\u20131335 (2021).","journal-title":"Br. J. Pharm."},{"key":"64622_CR54","doi-asserted-by":"publisher","unstructured":"Goutman, S. A. et al. Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol, https:\/\/doi.org\/10.1016\/S1474-4422(21)00414-2 (2022).","DOI":"10.1016\/S1474-4422(21)00414-2"},{"key":"64622_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03314-1","volume":"22","author":"QQ Duan","year":"2024","unstructured":"Duan, Q. Q. et al. TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitro. BMC Med. 22, 96 (2024).","journal-title":"BMC Med"},{"key":"64622_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2022.146821","volume":"844","author":"SK Kondapuram","year":"2022","unstructured":"Kondapuram, S. K. & Coumar, M. S. Pan-cancer gene expression analysis: Identification of deregulated autophagy genes and drugs to target them. Gene 844, 146821 (2022).","journal-title":"Gene"},{"key":"64622_CR57","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3233\/JPD-202138","volume":"10","author":"ML Erb","year":"2020","unstructured":"Erb, M. L. & Moore, D. J. LRRK2 and the Endolysosomal System in Parkinson\u2019s Disease. J. Parkinsons Dis. 10, 1271\u20131291 (2020).","journal-title":"J. Parkinsons Dis."},{"key":"64622_CR58","doi-asserted-by":"publisher","first-page":"E3349","DOI":"10.1073\/pnas.1523810113","volume":"113","author":"AS Moore","year":"2016","unstructured":"Moore, A. S. & Holzbaur, E. L. Dynamic recruitment and activation of ALS-associated TBK1 with its target optineurin are required for efficient mitophagy. Proc. Natl Acad. Sci. USA 113, E3349\u2013E3358 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"64622_CR59","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1007\/s12031-022-02071-1","volume":"72","author":"E Kubat Oktem","year":"2022","unstructured":"Kubat Oktem, E., Aydin, B., Yazar, M. & Arga, K. Y. Integrative Analysis of Motor Neuron and Microglial Transcriptomes from SOD1(G93A) Mice Models Uncover Potential Drug Treatments for ALS. J. Mol. Neurosci. 72, 2360\u20132376 (2022).","journal-title":"J. Mol. Neurosci."},{"key":"64622_CR60","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S1474-4422(18)30394-6","volume":"18","author":"DR Beers","year":"2019","unstructured":"Beers, D. R. & Appel, S. H. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol. 18, 211\u2013220 (2019).","journal-title":"Lancet Neurol."},{"key":"64622_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-017-0911-9","volume":"19","author":"HO Ohnstad","year":"2017","unstructured":"Ohnstad, H. O. et al. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up. Breast Cancer Res. 19, 120 (2017).","journal-title":"Breast Cancer Res"},{"key":"64622_CR62","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1136\/jnnp-2018-319785","volume":"90","author":"SA Goutman","year":"2019","unstructured":"Goutman, S. A. et al. High plasma concentrations of organic pollutants negatively impact survival in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 90, 907\u2013912 (2019).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"64622_CR63","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1136\/jnnp-2023-332121","volume":"95","author":"SA Goutman","year":"2024","unstructured":"Goutman, S. A. et al. Environmental risk scores of persistent organic pollutants associate with higher ALS risk and shorter survival in a new Michigan case\/control cohort. J. Neurol. Neurosurg. Psychiatry 95, 241\u2013248 (2024).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"64622_CR64","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1007\/s00420-022-01874-4","volume":"95","author":"SA Goutman","year":"2022","unstructured":"Goutman, S. A. et al. Associations of self-reported occupational exposures and settings to ALS: a case-control study. Int Arch. Occup. Environ. Health 95, 1567\u20131586 (2022).","journal-title":"Int Arch. Occup. Environ. Health"},{"key":"64622_CR65","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1101\/gr.261248.120","volume":"30","author":"AK Godfrey","year":"2020","unstructured":"Godfrey, A. K. et al. Quantitative analysis of Y-Chromosome gene expression across 36 human tissues. Genome Res. 30, 860\u2013873 (2020).","journal-title":"Genome Res"},{"key":"64622_CR66","doi-asserted-by":"crossref","unstructured":"Syage, A. R. et al. Single-cell RNA sequencing reveals the diversity of the immunological landscape following central nervous system infection by a murine coronavirus. J. Virol. 94 (2020).","DOI":"10.1128\/JVI.01295-20"},{"key":"64622_CR67","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s43018-022-00356-3","volume":"3","author":"T Chu","year":"2022","unstructured":"Chu, T., Wang, Z., Pe\u2019er, D. & Danko, C. G. Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology. Nat. Cancer 3, 505\u2013517 (2022).","journal-title":"Nat. Cancer"},{"key":"64622_CR68","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/nbt.3000","volume":"32","author":"S Li","year":"2014","unstructured":"Li, S. et al. Detecting and correcting systematic variation in large-scale RNA sequencing data. Nat. Biotechnol. 32, 888\u2013895 (2014).","journal-title":"Nat. Biotechnol."},{"key":"64622_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-022-02761-4","volume":"23","author":"HJ Zhou","year":"2022","unstructured":"Zhou, H. J., Li, L., Li, Y., Li, W. & Li, J. J. PCA outperforms popular hidden variable inference methods for molecular QTL mapping. Genome Biol. 23, 210 (2022).","journal-title":"Genome Biol."},{"key":"64622_CR70","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1371\/journal.pgen.0030161","volume":"3","author":"JT Leek","year":"2007","unstructured":"Leek, J. T. & Storey, J. D. Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet 3, 1724\u20131735 (2007).","journal-title":"PLoS Genet"},{"key":"64622_CR71","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1093\/nar\/gku864","volume":"42","author":"JT Leek","year":"2014","unstructured":"Leek, J. T. svaseq: removing batch effects and other unwanted noise from sequencing data. Nucleic Acids Res 42, e161 (2014).","journal-title":"Nucleic Acids Res"},{"key":"64622_CR72","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/00401706.1970.10488634","volume":"12","author":"AE Hoerl","year":"1970","unstructured":"Hoerl, A. E. & Kennard, R. W. Ridge regression: biased estimation for nonorthogonal problems. Technometrics 12, 55\u201367 (1970).","journal-title":"Technometrics"},{"key":"64622_CR73","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"1996","unstructured":"Tibshirani, R. Regression shrinkage and selection via the lasso. J. R. Stat. Soc.: Ser. B (Methodol.) 58, 267\u2013288 (1996).","journal-title":"J. R. Stat. Soc.: Ser. B (Methodol.)"},{"key":"64622_CR74","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1467-9868.2005.00503.x","volume":"67","author":"H Zou","year":"2005","unstructured":"Zou, H. & Hastie, T. Regularization and variable selection via the elastic net. J. R. Stat. Soc. Ser. B: Stat. Methodol. 67, 301\u2013320 (2005).","journal-title":"J. R. Stat. Soc. Ser. B: Stat. Methodol."},{"key":"64622_CR75","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s11432-010-0090-0","volume":"53","author":"Z Xu","year":"2010","unstructured":"Xu, Z., Zhang, H., Wang, Y., Chang, X. & Liang, Y. L1\/2 regularization. Sci. China Inf. Sci. 53, 1159\u20131169 (2010).","journal-title":"Sci. China Inf. Sci."},{"key":"64622_CR76","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1198\/016214501753382273","volume":"96","author":"J Fan","year":"2001","unstructured":"Fan, J. & Li, R. Variable selection via nonconcave penalized likelihood and its oracle properties. J. Am. Stat. Assoc. 96, 1348\u20131360 (2001).","journal-title":"J. Am. Stat. Assoc."},{"key":"64622_CR77","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1214\/09-AOS729","volume":"38","author":"C-H Zhang","year":"2010","unstructured":"Zhang, C.-H. Nearly Unbiased Variable Selection Under Minimax Concave Penalty.  Ann. Stat. 38, 894\u2013942 (2010).","journal-title":"Ann. Stat."},{"key":"64622_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinforma. 9, 559 (2008).","journal-title":"BMC Bioinforma."},{"key":"64622_CR79","unstructured":"Venables W. N., Ripley B. D. Modern applied statistics with S. Springer (2010)."},{"key":"64622_CR80","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1093\/bioinformatics\/btab869","volume":"38","author":"K Li","year":"2022","unstructured":"Li, K. et al. Efficient gradient boosting for prognostic biomarker discovery. Bioinformatics 38, 1631\u20131638 (2022).","journal-title":"Bioinformatics"},{"key":"64622_CR81","unstructured":"Therneau T., Grambsch P. Modeling survival data: Extending the cox model, 1 edn. Springer (2010)."},{"key":"64622_CR82","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1002\/sim.5958","volume":"32","author":"P Blanche","year":"2013","unstructured":"Blanche, P., Dartigues, J. F. & Jacqmin-Gadda, H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat. Med. 32, 5381\u20135397 (2013).","journal-title":"Stat. Med"},{"key":"64622_CR83","first-page":"1437","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian, A. et al. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000. Profiles Cell 171, 1437\u20131452.e1417 (2017).","journal-title":"Profiles Cell"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64622-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64622-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64622-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:02:48Z","timestamp":1761919368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64622-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["64622"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-64622-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"YZ: None. MGS: None. XL: None. KG: None. KW: None. ML: None. BL: None. GI: None. SAS: Listed as inventors on a patent, Issue number US10660895, held by the University of Michigan, titled \u201cMethods for Treating Amyotrophic Lateral Sclerosis,\u201d that targets immune pathways for use in ALS therapeutics. SAS has received unrelated research funding from NIH R01DK129320, which has no competing interest with this work. LZ: None. SJT: None. KMB None. JFD: None. BJT: BJT holds patents on the diagnostic and therapeutic implications of the C9orf72 repeat expansion. BJT has a patent pending (U.S. Patent Application No. 63\/717,807) on the diagnostic testing for ALS based on the proteomic panel. BJT has received unrelated research funding from Cerevel Therapeutics and the ALS Association, which have no competing interest with this work. BJT holds a leadership role in an Advisory Committee of the American Neurological Association. BJT serves on the editorial board of EClinicalMedicine and JNNP and is an associate editor for Brain. BJT also has collaborative research agreements with Ionis Pharmaceuticals, Roche, and Optimeos. AK: None. SAB: None. JH: None. SAG: Listed as inventors on a patent, Issue number US10660895, held by the University of Michigan titled \u201cMethods for Treating Amyotrophic Lateral Sclerosis\u201d that targets immune pathways for use in ALS therapeutics. Scientific consulting for Evidera. Payment from the American Academy of Neurology. MAS: None. ELF: ELF is listed as an inventor on a patent, Issue number US10660895, held by the University of Michigan titled \u201cMethods for Treating Amyotrophic Lateral Sclerosis\u201d that targets immune pathways for use in ALS therapeutics. ELF has received unrelated funding from NIH, CDC\/ATSDR, DoD, Breakthrough T1D, and the American Heart Association, which have no competing interest with this work. ELF was a member of the National Academy of Sciences, Engineering, and Medicine, Committee on Making ALS a Livable Disease.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9631"}}